https://www.selleckchem.com/pr....oducts/tiragolumab-a
67% of patients in the PP group, and 27.91% in the non-PP group. After adjustment for age, gender, CT grade and APACH II score, the odd ratio remain significant (OR 5.47, 95% confidence interval [CI] 1.84-16.25, p = 0.002). Furthermore, in patients with lower TC level, no significant difference was found in primary outcome between PP group and non-PP group (81.25% versus 62.30%, adjusted OR 2.05; 95% CI 0.45-9.40; p = 0.353). TC could be a potential biomarker to predict the effects of TG-lowing therapy in patients with HL
Gefällt mir
Kommentar
Teilen
